August 23, 2022
Chugai Pharmaceutical has acquired the rights to use Noile-Immune Biotech’s PRIME (proliferation-inducing and migration-enhancing) technology to develop CAR-T cell therapies for solid tumors, the companies said on August 22. The PRIME technology, developed by the Yamaguchi University/National Cancer Center spinoff,...read more